These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27071349)

  • 1. Health policy: Addressing conflicts of interest of public speakers at advisory committee meetings.
    McCoy MS; Emanuel EJ
    Nat Rev Clin Oncol; 2016 May; 13(5):267-8. PubMed ID: 27071349
    [No Abstract]   [Full Text] [Related]  

  • 2. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.
    Hayes MJ; Prasad V
    Hastings Cent Rep; 2018 Mar; 48(2):10-13. PubMed ID: 29590518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.
    Lurie P; Almeida CM; Stine N; Stine AR; Wolfe SM
    JAMA; 2006 Apr; 295(16):1921-8. PubMed ID: 16639051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration.
    Abola MV; Prasad V
    JAMA Intern Med; 2016 Mar; 176(3):389-91. PubMed ID: 26831527
    [No Abstract]   [Full Text] [Related]  

  • 5. Characteristics and conflicts of interests of public speakers at the Psychopharmacologic Drug and Advisory Committee meetings regarding psychiatric drugs.
    Roberts W; Jellison S; Wayant C; Vassar M
    BMJ Evid Based Med; 2020 Aug; 25(4):145-146. PubMed ID: 32019896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Effects of Financial Conflicts of Interest of Speakers at the US Food and Drug Administration's Pulmonary-Allergy Drug Advisory Committee Meetings.
    Bickford T; Kinder N; Arthur W; Wayant C; Vassar M
    Chest; 2021 Jun; 159(6):2399-2401. PubMed ID: 33171160
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Conflicts of Interest for Public Speakers for the Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration With Their Statements.
    Arthur W; Austin J; Wayant C; Vassar M
    JAMA Neurol; 2019 Mar; 76(3):368-369. PubMed ID: 30556837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of Appearance of Conflicts of Interest With Voting Behavior at FDA Advisory Committee Meetings-A Cross-sectional Study.
    Xu J; Emenanjo O; Ortwerth M; Lurie P
    JAMA Intern Med; 2017 Jul; 177(7):1038-1040. PubMed ID: 28464118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial conflicts of interest during meetings of the cardiovascular and renal drugs advisory committee.
    Bertolino B; Kinder N; Cooper C; Gray H; Arthur W; Ahlander J; Simpson A; Vassar M
    J Osteopath Med; 2022 Sep; 122(9):445-451. PubMed ID: 35447023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conflicts of Interest of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products Advisory Committee.
    McCoy MS; Pagán O; Donohoe G; Kanter GP; Litman RS
    JAMA Intern Med; 2018 Jul; 178(7):996-997. PubMed ID: 29710219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial conflicts of interest and the Food and Drug Administration's Advisory Committees.
    Steinbrook R
    N Engl J Med; 2005 Jul; 353(2):116-8. PubMed ID: 16014880
    [No Abstract]   [Full Text] [Related]  

  • 13. Disclosing the Conflicts of Interest of US Food and Drug Administration Advisory Committee Members.
    Steinbrook R
    JAMA Intern Med; 2017 Jul; 177(7):919. PubMed ID: 28464117
    [No Abstract]   [Full Text] [Related]  

  • 14. Oncologic Drugs Advisory Committee and conflicts of interest.
    Burki TK
    Lancet Oncol; 2016 Mar; 17(3):e95. PubMed ID: 26877161
    [No Abstract]   [Full Text] [Related]  

  • 15. Public Speaker Characteristics at Meetings of the Dermatologic and Ophthalmic Drug Advisory Committee and the Ophthalmic Devices Panel.
    Khattab MH; Weaver M; Cook C; Kinder N; Vassar M
    Am J Ophthalmol; 2021 Mar; 223():28-32. PubMed ID: 33166500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting financial conflicts of interest in FDA advisory committees.
    Pham-Kanter G
    Milbank Q; 2014 Sep; 92(3):446-70. PubMed ID: 25199895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings.
    Lammers A; Edmiston J; Kaestner V; Prasad V
    Mayo Clin Proc; 2017 Jul; 92(7):1164-1166. PubMed ID: 28688469
    [No Abstract]   [Full Text] [Related]  

  • 18. Conflicts cause FDA to review advisory committees.
    Kondro W
    CMAJ; 2006 Jul; 175(1):23. PubMed ID: 16818900
    [No Abstract]   [Full Text] [Related]  

  • 19. Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees.
    Graham SS; Card DJ; Ahn S; Kim SY; Kessler MM; Olson MK
    Ann Intern Med; 2016 Oct; 165(8):606-607. PubMed ID: 27750309
    [No Abstract]   [Full Text] [Related]  

  • 20. Advisory committees at FDA: the Hinchey Amendment and "conflict of interest" waivers.
    Lietzan E
    J Health Law; 2006; 39(4):415-49. PubMed ID: 17402656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.